Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of “Buy” by Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have earned a consensus rating of “Buy” from the ten analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $21.4444.

A number of equities analysts have commented on TRVI shares. B. Riley raised shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, November 17th. D. Boral Capital restated a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a research note on Friday, November 14th. Leerink Partners lifted their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Oppenheimer upped their price target on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, October 8th.

Trevi Therapeutics Stock Down 2.4%

Shares of NASDAQ TRVI opened at $12.11 on Thursday. The business’s 50 day moving average price is $11.61 and its two-hundred day moving average price is $8.81. The company has a market cap of $1.55 billion, a PE ratio of -32.73 and a beta of 0.83. Trevi Therapeutics has a twelve month low of $3.47 and a twelve month high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02. As a group, research analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC raised its holdings in Trevi Therapeutics by 7.2% in the 1st quarter. Acorn Capital Advisors LLC now owns 2,144,844 shares of the company’s stock valued at $13,491,000 after acquiring an additional 143,796 shares in the last quarter. Vivo Capital LLC increased its position in shares of Trevi Therapeutics by 28.7% in the second quarter. Vivo Capital LLC now owns 4,487,903 shares of the company’s stock worth $24,549,000 after purchasing an additional 1,000,000 shares during the period. Prudential Financial Inc. acquired a new position in Trevi Therapeutics in the second quarter valued at about $1,238,000. Jefferies Financial Group Inc. bought a new stake in Trevi Therapeutics during the second quarter worth about $301,000. Finally, AXQ Capital LP acquired a new stake in Trevi Therapeutics during the second quarter worth about $227,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.